Abstract:The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the effect of therapy twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point.
References and links1. J. Folkman, "What is the evidence that tumors are angiogenesis dependent?" J. Natl. Cancer Inst. 82(1), 4-6 (1990). 2. J. Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," Nat. Med. 1(1), 27-30 (1995). 3. P. Carmeliet and R. K. Jain, "Angiogenesis in cancer and other diseases," Nature 407(6801), 249-257 (2000). 4. N. Ferrara, H.-P. Gerber, and J. LeCouter, "The biology of VEGF and its receptors," Nat. Med. 9(6), 669-676 (2003). 5. J. Folkman, "Angiogenesis: an organizing principle for drug discovery?" Nat. Rev. Drug Discov. 6(4), 273-286 (2007). 6. L. M. Ellis and D. J. Hicklin, "VEGF-targeted therapy: mechanisms of anti-tumour activity," Nat. Rev. Cancer 8(8), 579-591 (2008